Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

NCT03964090 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

NIH

Sponsor class

Conditions

Central Nervous System Lymphoma
Secondary Central Nervous System Lymphoma

Interventions

DRUG: TEDD-R
DRUG: TEDDI-R
DRUG: Ibrutinib
DRUG: Cytarabine
DRUG: Isavuconazole
DRUG: Methotrexate

Sponsor

National Cancer Institute (NCI)